Oeckl P, Halbgebauer S, Anderl-Straub S, Steinacker P, Huss AM, Neugebauer H, Von Arnim CAF, Diehl-Schmid J, Grimmer T, Kornhuber J, Lewczuk P, Danek A, Ludolph AC, Otto M (2019)
Publication Type: Journal article
Publication year: 2019
Book Volume: 67
Pages Range: 481-488
Journal Issue: 2
DOI: 10.3233/JAD-180325
Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r = -0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.
APA:
Oeckl, P., Halbgebauer, S., Anderl-Straub, S., Steinacker, P., Huss, A.M., Neugebauer, H.,... Otto, M. (2019). Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. Journal of Alzheimer's Disease, 67(2), 481-488. https://doi.org/10.3233/JAD-180325
MLA:
Oeckl, Patrick, et al. "Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment." Journal of Alzheimer's Disease 67.2 (2019): 481-488.
BibTeX: Download